OSTEOPOROZ: TOChKA ZRENIYa ENDOKRINOLOGA


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

Data on the main calcium-regulating hormones (parathyroid hormone, calcitonin) and their role in the regulation of bone remodeling are presented. These processes are also influenced by sex steroids, growth hormone, insulin, cortisol, thyroid hormones, and various local growth factors. In this regard, osteopenia and osteoporosis are closely linked with a number of endocrine diseases, some of which are common (diabetes mellitus, thyrotoxicosis), others - quite rare (endogenous hypercortisolism). The osteoporosis associated with diabetes, steroid osteoporosis, osteoporosis associated with thyroid function abnormalities are discussed in detail. It is emphasized that timely diagnosis and adequate treatment of endocrine diseases associated with decreased bone mineral density contribute to slowing or termination of bone loss, normalization of bone remodeling, can reduce the incidence of fractures and improve quality of life.

Толық мәтін

Рұқсат жабық

Авторлар туралы

Elena Biryukova

Email: lena@obsudim.ru

Әдебиет тізімі

  1. Риггз Б.Л., Мелтон III Л.Д. Остеопороз. Этиология, диагностика, лечение. М., 2000.
  2. Руководство по остеопорозу / Под ред. Л.И. Беневоленской. М., 2003.
  3. Painter S.E., Kleerekoper M., Camacho P.M. Secondary osteoporosis: a review of the recent evidence. Endocr Pract 2006; 12(4): 436-45.
  4. Davidson M.R. Pharmacotherapeutics for osteoporosis prevention and treatment. J Midwifery Womens Health 2003; 48: 39-52.
  5. Рациональная фармакотерапия заболеваний эндокринной системы и нарушений обмена веществ: Руководство для практикующих врачей / Под общ. ред. И.И. Дедова, Г.А. Мельниченко. М., 2006.
  6. Шварц Г.Я. Фармакотерапия остеопороза. М., 2002.
  7. Eastell R. Treatment of Postmenopausal Osteoporosis. N Engl Med J 1998; 338(11): 736-46.
  8. Heaney R.P., Weaver C.M. Calcium and vitamin D. Endocrin Metab Clin NA 2003; 32(1): 181-94.
  9. Peacock M. Calcium metabolism in health and disease. CJASN 2010; 5: S23-S30.
  10. Schacht E., Richy F., Reginster J.-Y. The therapeutic effects of alfacalcidol on bone strength, muscle metabolism and prevention of falls and fractures. J Musculoskelet Neuronal Interact 2005; 5(3): 273-84.
  11. Steingrimsdottir L., Gunnarsson O., Indridason O.S., et al. Relationship between serum parathyroid hormone levels, vitamin D sufficiency, and calcium intake. JAMA 2005; 294(18): 2336-41.
  12. Lin R., White J.H. The pleiotropic actions of vitamin D. Bioessays 2004; 26(1): 21-8.
  13. Hathcock J.N., Shao A., Vieth R., Heaney R. Risk assessment for Vitamin D. Am J Clin Nutr 2007; 85(1): 6-18.
  14. Schwait A.V. Diabetes Mellitus: Does it Affect Bone? Calcif Tissue Int 2003; 73(6): 515-19.
  15. Schwartz A.V., Sellmeyer D.E. Diabetes, fracture, and bone fragility. Curr Osteoporos Rep 2007; 5(3): 105-11.
  16. Lecka-Czernik B. Bone as a target of type 2 diabetes treatment. Curr Opin Investig Drugs 2009; 10(10): 1085-90.
  17. Pittas A.G., Lau J., Hu F., Dawson-Hughes B. The role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis. J Clin Endocrinol Metab 2007; 92(6): 2017-29.
  18. Hofbauer L.C., Brueck C.C., Singh S.K., Dobnig H. Osteoporosis in patients with diabetes mellitus. J Bone Miner Res 2007; 22: 1317-28.
  19. Schwartz A.V., Sellmeyer D.E., Vittinghoff E., et al. Thiazolidinedione use and bone loss in older diabetic adults. J Clinical Endocrinol Metab 2006; 91: 3349-54.
  20. Баранова И.А. Глюкокортикоидиндуцированный остеопороз: патогенез, профилактика, лечение // Современная ревматология 2008. № 1. С. 31-9.
  21. Kanis J.A., Johansson H., Oden A., et al. A metaanalysis of prior corticosteroid use and fracture risk. J Bone Miner Res 2004; 19; 893-99.
  22. Hofbauer L.C., Rauner M. Live and let die: effects of glucocorticoids on bone cells. Molec Endocrinol 2009; 23: 1525-31.
  23. Canalis E., Mazziotti G., Giustina A., Bilezikian J.P. Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporosis International 2007; 18: 1319-28.
  24. Al-Abadi A.C. Subclinical thyrotoxicosis. Postgrad Med J 2001; 29(7): 220-28.
  25. Williams G.R. Actions of thyroid hormones in bone. Endokrynol Pol 2009; 60(5): 380-88.
  26. Bauer D.C., Ettinger B., Nevitt M.C., Stone K.L. Risk for fracture in women with low serum levels of thyroid-stimulating hormone. Annals of Internal Medicine 2001; 134: 561-68.
  27. Heemstra K.A., Hamdy N.A., Romijn J.A., Smit J.W. The effects of thyrotropin suppressive therapy on bone metabolism in patients with well-differentiated thyroid carcinoma. Thyroid 2006; 16: 583-91.
  28. Bilezikian J.P., Silverberg S.J. Clinical Spectrum of Primary Treatment Hyperparathyroidism. Reviews in endocrine and metab disorders. 2000; 1: 237-45.
  29. Rubin M.R., Bilezikian J.P., McMahon D.J., et al. The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years. J Clin Endocrinol Metab 2008; 93: 3462-70.
  30. Nguyen T.V., Center J.R., Eisman J.A. Osteoporosis: underdiagnosed and undertreated. Med J Aust 2004; 180(5): 18-22.
  31. Kärkkäinen M.K., Tuppurainen M., Salovaara K. Does daily vitamin D 800 IU and calcium 1000 mg supplementation decrease the risk of falling in ambulatory women aged 65-71 years? A 3-year randomized population-based trial (OSTPRE-FPS). Maturitas 2010; 65(4): 359-65.
  32. Лесняк Ю.Ф., Лесняк O.M. Анализ минимизации и эффективности затрат на профилактику остеопороза препаратами кальция и витамина D // Российский семейный врач 2004. № 1. С. 22-27.
  33. Hofbauer L.C., Hamann C., Ebeling P.R. Approach to the patient with secondary osteoporosis. Eur J End 2010; 162: 1009-20.
  34. Saag K.G., Shane E., Boonen S., et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl Med J 2007; 357: 2028-39.
  35. Reid D.M., Devogelaer J.P., Saag K., et al. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 2009; 373: 1253-63.
  36. Emkey R., Koltun W., Beusterien K., et al. Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO). Curr Med Res Opin 2005; 21(12): 1895-903.
  37. Richy F., Ethgen O., Bruyere O., Reginster J.-Y. Efficacy of alphacalcidol and calcitriol in primary and corticosteroid-induced osteoporosis: a meta-analysis of their effects on bone mineral density and fracture rate. Osteoporos Int 2004; 15: 301-10.
  38. Tanizawa T., Imura K., Ishii Y., et al. Treatment with active vitamin D metabolites and concurrent treatments in the prevention of hip fractures: a retrospective study. Osteoporos Int 1999; 9: 163-70.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bionika Media, 2012